Sunitinib V. Pazopanib in the First Line Setting  Patients receiving sunitinib had better overall survival

Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had better overall survival

kidneycancer

2 years
55 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had better overall survival at Kidney Cancer Association 2017 in Miami.
Up Next Autoplay